On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Fujian South Pharmaceutical Co.,Ltd.

23 YRS

Fujian, China

CNY 120.5 Million

133200 m²

100-500 people

Main Products: Paclitaxel / Docetaxel / Bendamustine HCL Monohydrate / Letrozole / Pemetrexed Disodium Hemipentahydrate / Azacytidine

Fujian, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Letrozole / CAS 112809-51-5

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Letrozole

English Name: letrozole

CAS No.: 112809-51-5

Molecular formula: C17H11N5

Molecular weight: 285.3

EINECS No.: 675-034-8

Purpose: letrozole is a new generation of highly selective aromatase inhibitor. It is a synthetic benzyltriazole derivative. It can reduce the level of estrogen by inhibiting aromatase, so as to eliminate the stimulating effect of estrogen on tumor growth. The activity in vivo is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect glucocorticoid, mineralocorticoid and thyroid function, and high-dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index.

Typical Properties

Letrozole is a new generation of highly selective aromatase inhibitor, which is a synthetic benzyltriazole derivative. By inhibiting aromatase, letrozole can reduce the level of estrogen, so as to eliminate the stimulating effect of estrogen on tumor growth. The in vivo activity is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect the function of glucocorticoid, mineralocorticoid and thyroid. High dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Preclinical studies have shown that letrozole has no potential toxicity, mutagenic and carcinogenic effects on various systems and target organs of the body, and has less toxic and side effects, good tolerance. Compared with other aromatase inhibitors and anti estrogen drugs, letrozole has stronger anti-tumor effect. It is suitable for the treatment of patients with advanced breast cancer who are not effective in the treatment of estrogen and early treatment of breast cancer.

CAS No.

112809-51-5

Formula

C17H11N5

Molecular Mass

285.3027

Exact Mass

285.10100

PSA

78.29000

Logp

2.65916

IUPAC

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile

SMILES

C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3

Matter Classification

organic

GET SAMPLE